SCHEMBL21902011

SCHEMBL21902011

Cc1cn(-c2cc(O)cc(C(C)(C)C)c2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR2E1 Q9Y466 13/20 0.51
GABRA1 P14867 1/20 0.46
GABRB2 P47870 1/20 0.46
CYP2E1 P05181 1/20 0.40
CYP2A6 P11509 1/20 0.40
NTRK1 P04629 1/20 0.39
DDR1 Q08345 1/20 0.39
NTRK3 Q16288 1/20 0.39
NTRK2 Q16620 1/20 0.39
DDR2 Q16832 1/20 0.39
OPRD1 P41143 2/20 0.37
PTK2 Q05397 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
OPRM1 P35372 1/20 0.36
OPRK1 P41145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12372948 0.89 NR2E1 (0.58) NR2E1CYP2E1CYP2A6NTRK1DDR1
SCHEMBL15315567 0.84 NR2E1 (0.54) NR2E1CYP2E1CYP2A6NTRK1DDR1
SCHEMBL9609575 0.81 NR2E1 (0.71) NR2E1
SCHEMBL29186581 0.78 MAOA (0.47) NR2E1CYP2E1CYP2A6CYP1A2CYP3A4
SCHEMBL30050455 0.78 MAOA (0.47) NR2E1CYP2E1CYP2A6CYP1A2CYP3A4
SCHEMBL10183719 0.76 CYP2E1 (0.51) NR2E1CYP2E1CYP2A6NTRK1DDR1
SCHEMBL22604349 0.76 CYP2E1 (0.51) NR2E1CYP2E1CYP2A6OPRD1CYP1A2
SCHEMBL270618 0.75 CYP1A2 (0.53) NR2E1CYP2E1CYP2A6PTK2CYP1A2
SCHEMBL29556509 0.73 CYP11B1 (0.50) GABRA1GABRB2CYP2A6CYP3A4CYP19A1
SCHEMBL18289106 0.73 CYP11B1 (0.50) GABRA1GABRB2CYP2A6CYP3A4CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200123165-A1 KINASE INHIBITORS INSILICO MEDICINE LTD. (CN) 2020-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123165-A1 KINASE INHIBITORS DDR1, DDR2, DDRGK1 NR2E1 579/4885GABRA1 2963/4885GABRB2 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.